Efficacy and safety of bevacizumab in patients with low-grade serous ovarian cancer

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

• 1. Grisham RN, Chui MH. Advancements in low-grade serous carcinoma of the ovary and peritoneum. Curr. Oncol. Rep. 24(11), 1549–1555 (2022). •• Treatment options in low-grade serous ovarian cancer.
  Medline CASGoogle Scholar
• 2. Hollis RL. Molecular characteristics and clinical behaviour of epithelial ovarian cancers. Cancer Lett. 216057 (2023).
  MedlineGoogle Scholar
• 3. Babaier A, Mal H, Alselwi W, Ghatage P. Low-grade serous carcinoma of the ovary: the current status. Diagnostics 12(2), 458 (2022).
  Medline CASGoogle Scholar
• 4. Zwimpfer TA, Tal O, Geissler F et al. Low grade serous ovarian cancer–a rare disease with increasing therapeutic options. Cancer Treat. Rev. 112, 102497 (2022).
  MedlineGoogle Scholar
• 5. Manning-Geist B, Gordhandas S, Liu YL et al. MAPK pathway genetic alterations are associated with prolonged overall survival in low-grade serous ovarian carcinoma. Clin. Cancer Res. 28(20), 4456–4465 (2022).
  Medline CASGoogle Scholar
• 6. Armstrong DK, Alvarez RD, Bakkum-Gamez JN et al. Ovarian Cancer, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology. J. Natl Comprehens. Cancer Network 19(2), 191–226 (2021).
  CASGoogle Scholar
• 7. Grabowski JP, Vila CM, Richter R et al. Ki67 expression as a predictor of chemotherapy outcome in low-grade serous ovarian cancer. Int.J.Gynecol.Cancer 30(4), 498–503 (2020).
  MedlineGoogle Scholar
• 8. Cheasley D, Fernandez ML, Köbel M et al. Molecular characterization of low-grade serous ovarian carcinoma identifies genomic aberrations according to hormone receptor expression. NPJ Precis. Oncol. 6(1), 47 (2022). • Describes the molecular characterization of low-grade serous ovarian carcinoma.
  Medline CASGoogle Scholar
• 9. Cheasley D, Nigam A, Zethoven M et al. Genomic analysis of low‐grade serous ovarian carcinoma to identify key drivers and therapeutic vulnerabilities. J. Pathol. 253(1), 41–54 (2021).
  Medline CASGoogle Scholar
• 10. Gershenson DM, Miller A, Brady WE et al. Trametinib versus standard of care in patients with recurrent low-grade serous ovarian cancer (GOG 281/LOGS): an international, randomised, open-label, multicentre, phase 2/3 trial. Lancet 399(10324), 541–553 (2022).
  Medline CASGoogle Scholar
• 11. Moujaber T, Balleine RL, Gao B, Madsen I, Harnett PR, DeFazio A. New therapeutic opportunities for women with low-grade serous ovarian cancer. Endocr.-Relat. Cancer 29(1), R1–R16 (2022). •• Discusses the treatment options in low-grade serous ovarian cancer.
  CASGoogle Scholar
• 12. Apte RS, Chen DS, Ferrara N. VEGF in signaling and disease: beyond discovery and development. Cell 176(6), 1248–1264 (2019).
  Medline CASGoogle Scholar
• 13. Haunschild CE, Tewari KS. Bevacizumab use in the frontline, maintenance and recurrent settings for ovarian cancer. Future Oncol. 16(7), 225–246 (2020).
  CASGoogle Scholar
• 14. Mao C-L, Seow K-M, Chen K-H. The utilization of bevacizumab in patients with advanced ovarian cancer: a systematic review of the mechanisms and effects. Int. J. Mol. Sci. 23(13), 6911 (2022).
  Medline CASGoogle Scholar
• 15. Dalton HJ, Fleming ND, Sun CC, Bhosale P, Schmeler KM, Gershenson DM. Activity of bevacizumab-containing regimens in recurrent low-grade serous ovarian or peritoneal cancer: a single institution experience. Gynecol. Oncol. 145(1), 37–40 (2017). • Discusses the efficacy of bevacizumab in low-grade serous ovarian cancer.
  Medline CASGoogle Scholar
• 16. Grisham RN, Iyer G, Sala E et al. Bevacizumab shows activity in patients with low-grade serous ovarian and primary peritoneal cancer. Int. J. Gynecol. Cancer 24(6), 1010–1014 (2014). •• Discusses the efficacy of bevacizumab in low-grade serous ovarian cancer.
  MedlineGoogle Scholar
• 17. Bidus MA, Webb JC, Seidman JD, Rose GS, Boice CR, Elkas JC. Sustained response to bevacizumab in refractory well-differentiated ovarian neoplasms. Gynecol. Oncol. 102(1), 5–7 (2006).
  Medline CASGoogle Scholar
• 18. Schmeler K, Tao X, Sun C et al. Encouraging responses with bevacizumab in recurrent low-grade serous ovarian cancer. J. Clin. Oncol. 28(Suppl. 15), e15503–e15503 (2010).
  Google Scholar
• 19. Rose PG, Mahdi H, Jernigan A, Yang B. Activity of bevacizumab in patients with low-grade serous ovarian carcinoma. Int. J. Gynecol.Cancer 26(6), 1048–1052 (2016). • Discusses the efficacy of bevacizumab in low-grade serous ovarian cancer.
  MedlineGoogle Scholar
• 20. Musacchio L, Turinetto M, Arenare L et al. Effect of bevacizumab in advanced low grade serous ovarian cancer: data from the MITO 22 trial. Gynecol. Oncol. 172, 72–77 (2023). •• Discusses the efficacy of bevacizumab in low-grade serous ovarian cancer.
  Medline CASGoogle Scholar
• 21. Monk BJ, Grisham RN, Banerjee S et al. MILO/ENGOT-ov11: binimetinib versus physician's choice chemotherapy in recurrent or persistent low-grade serous carcinomas of the ovary, fallopian tube, or primary peritoneum. J. Clin. Oncol. 38(32), 3753 (2020).
  Medline CASGoogle Scholar
• 22. Hollis RL, Thomson JP, van Baal J et al. Distinct histopathological features are associated with molecular subtypes and outcome in low grade serous ovarian carcinoma. Sci. Rep. 13(1), 7681 (2023).
  Medline CASGoogle Scholar
• 23. Yokoyama Y, Kubo-Kaneda M, Sunada K et al. Adverse events associated with long-term treatment of epithelial ovarian cancer with bevacizumab and chemotherapy. Anticancer Res. 42(8), 4165–4171 (2022).
  Medline CASGoogle Scholar
• 24. Nanki Y, Nomura H, Iwasa N et al. A prospective cohort study on the safety and efficacy of bevacizumab combined with chemotherapy in Japanese patients with relapsed ovarian, fallopian tube or primary peritoneal cancer. Japan. J. Clin. Oncol. 51(1), 54–59 (2021).
  MedlineGoogle Scholar
• 25. Akilli H, Rahatli S, Aliyeva K, Altundag O, Kuscu UE, Ayhan A. Survival in recurrent ovarian cancer patients before and after the bevacizumab era: an observational single-centre study. J. Obstet. Gynaecoly. 42(6), 2230–2234 (2022).
  Medline CASGoogle Scholar